BenevolentAl Therapeutics Pipeline and Triage
Glioblastoma Multiforme (GBM)
One of the most lethal and aggressive brain tumours
• Extremely poor prognosis and high unmet need
Prevalence
• Incidence of GBM ranges from 0.59 to 5 per 100,000 (1)
• Mean age at presentation 53y, 5 year survival rate - 5%
Standard of Care (SoC)
Surgery, Radio- & Chemotherapy, Temozolomide (TMZ)
• Current therapy rarely curative
Glioblastoma Stem Cells - key component
•
Self renewal
Resistant to radio & Chemotherapy
Highly infiltrative and heterogeneous
MES-Aggressive; Poor survival
о
PN- Favourable outcome
CL- Best response to therapy
Reasons why GBM has high unmet need
• Tumour intrinsic
о
。 Glioblastoma Stem Cells (GSC)
⚫ High level of Tumour heterogeneity
О
。 Tumour Micro environment (TME)
О
⚫ Rapid evolution of the tumour and its
transition into aggressive phenotype
KOL most cited reason for therapy failure
Lack of effective BBB penetrant molecules
Source (1) 1- Grech et al. 2020, DOI: 10.7759/cureus.8195View entire presentation